These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 28635104)

  • 1. Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients-or educational mismatch?
    Dirks M; Pflugrad H; Weissenborn K
    J Viral Hepat; 2017 Nov; 24(11):1078. PubMed ID: 28635104
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistent neuropsychiatric impairment in HCV patients-or educational mismatch?
    Gade A
    J Viral Hepat; 2017 Nov; 24(11):1077. PubMed ID: 28632929
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.
    Monaco S; Mariotto S; Ferrari S; Calabrese M; Zanusso G; Gajofatto A; Sansonno D; Dammacco F
    World J Gastroenterol; 2015 Nov; 21(42):11974-83. PubMed ID: 26576086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV and dermatomyositis: report of 5 cases of dermatomyositis in patients with HCV infection.
    Fiore G; Giacovazzo F; Giacovazzo M
    Riv Eur Sci Med Farmacol; 1996; 18(5-6):197-201. PubMed ID: 9177622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation.
    Huang EJ; Wright TL; Lake JR; Combs C; Ferrell LD
    Hepatology; 1996 Mar; 23(3):396-404. PubMed ID: 8617417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review.
    Shah HA; Abu-Amara M
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):922-33. PubMed ID: 23639601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of hepatitis C virus (HCV) viremia and adaptation of HCV in persistent infection in patients with acute hepatitis].
    Tanaka E
    Nihon Rinsho; 1994 Jul; 52(7):1852-6. PubMed ID: 7521430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus.
    Gowans EJ; Jones KL; Bharadwaj M; Jackson DC
    J Clin Virol; 2004 Aug; 30(4):283-90. PubMed ID: 15163415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive impairment in relation to depression, anxiety and virological response in hepatitis C patients in Egypt.
    Bassiony MM; Yousef A; Raya Y; El-Shabrawi A; Fouad E; El-Shafeey M
    Int J Psychiatry Clin Pract; 2015; 19(3):208-15. PubMed ID: 26099337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of serologic testing for hepatitis C virus infection and risk of posttransfusion hepatitis C.
    Alter MJ
    Arch Pathol Lab Med; 1994 Apr; 118(4):342-5. PubMed ID: 7513149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C.
    Barrera JM; Bruguera M; Ercilla MG; Gil C; Celis R; Gil MP; del Valle Onorato M; Rodés J; Ordinas A
    Hepatology; 1995 Mar; 21(3):639-44. PubMed ID: 7533121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Care Perspectives on Hepatitis C Virus Screening, Diagnosis and Linking Patients to Appropriate Care.
    Lebovics E; Torres R; Porter LK
    Am J Med; 2017 Feb; 130(2):S1-S2. PubMed ID: 28087291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between IL-10 gene polymorphisms and the outcomes of hepatitis C virus infection among high risk populations in Jiangsu province].
    Tang LY; Wang J; Yu RB; Su J; Xu K; Peng ZH; Deng XZ; Ding WL; Ge ZJ; Zhang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Sep; 33(9):898-902. PubMed ID: 23290798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
    Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-hepatitis C antibodies in patients with chronic non-A, non-B hepatitis: relation to disease progression and effect of interferon alpha.
    Yoshioka K; Kakumu S; Hayashi H; Shinagawa T; Wakita T; Ishikawa T; Itoh Y; Takayanagi M
    Am J Gastroenterol; 1991 Oct; 86(10):1495-9. PubMed ID: 1928044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening for post-transfusion hepatitis C-importance of enrollment and recall of blood transfusion recipients].
    Matsuoka S
    Nihon Koshu Eisei Zasshi; 1994 Sep; 41(9):933-7. PubMed ID: 7524804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to "Hepatitis C virus, sickle cell disease treatment options"--a February letter to the editor.
    Smoot DT
    J Natl Med Assoc; 2004 Mar; 96(3):383. PubMed ID: 15040523
    [No Abstract]   [Full Text] [Related]  

  • 18. High efficiency prokaryotic expression and purification of a portion of the hepatitis C core protein and analysis of the immune response to recombinant protein in BALB/c mice.
    Hitomi Y; McDonnell WM; Baker JR; Askari FK
    Viral Immunol; 1995; 8(2):109-19. PubMed ID: 8825296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The diagnostic significance of anti-HCV IgM in chronic hepatitis C viral infection].
    Wu H; Wang J; Lin X
    Zhonghua Nei Ke Za Zhi; 1995 Jan; 34(1):42-5. PubMed ID: 7541329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
    Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.